<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00788008</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00010070</org_study_id>
    <nct_id>NCT00788008</nct_id>
  </id_info>
  <brief_title>Cognitive Effects of Inhalational Versus Intravenous General Anesthesia in the Elderly</brief_title>
  <official_title>Does Inhalational Anesthesia Accelerate Postoperative Cognitive Decline?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to determine if post-operative cognition will be better if
      the general anesthesia for surgery is done with an inhaled (gas through a breathing tube) or
      intravenous (medicine injected in the IV) general anesthetic technique.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective randomized pre-test post-test design will be used. After obtaining informed
      consent, patients will be randomized to either: 1) Inhalational anesthesia with isoflurane or
      2) Total intravenous anesthesia(TIVA) with propofol. Randomization will be stratified by
      surgical type so that this variable is equally distributed between the treatment groups. All
      patients will be maintained at a standard depth of anesthesia (40-60) using a Bispectral
      Index (BIS®) monitor. Normocarbia will be maintained in the operating room using capnography
      monitoring. Normothermia will be maintained throughout the procedure.

      The anesthesia team providing care for these patients will be able to choose the
      premedication and muscle relaxant for the anesthetic technique. Patient controlled anesthesia
      or regional anesthetic techniques may be used for post-operative analgesia at the discretion
      of the anesthesia team providing care for these patients. Anesthesia will be induced with
      intravenous propofol and fentanyl in all patients, unless contraindicated. Patients will be
      mechanically ventilated with air/oxygen. Temperature will be maintained &gt; 35º C and
      ventilation will be adjusted to maintain end-tidal carbon dioxide (CO2) at 35 ± 5 mmHg. Mean
      arterial pressure will be maintained ≥ 75% of baseline or ≥ 60 mmHg, whichever is greater, in
      both groups. After induction of anesthesia, the maintenance anesthesia will consist of
      either:

        1. Inhalational anesthesia group - isoflurane will be used for maintenance of anesthesia.
           Intravenous fentanyl and/or remifentanil will be used for supplementary analgesia. These
           agents will be administered to maintain a normal depth of anesthesia using the BIS®
           monitor and traditional signs of anesthetic depth.

        2. TIVA group - propofol and opioid infusions (fentanyl or remifentanil) will be used for
           the maintenance of anesthesia. The infusions will be adjusted to maintain a normal depth
           of anesthesia using the BIS® monitor along with traditional signs of anesthetic depth.

      All subjects will undergo pre-operative neurocognitive testing within two weeks of their
      surgery, and at 3 months post-surgery. The persistence versus resolution of cognitive
      deficits over time will be determined with a 1 year post-surgical follow-up assessment. Pre-
      to post-test change scores will be compared across groups on primary and secondary outcome
      variables (see below) while controlling for relevant demographic variables (age, education,
      sex).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Neurocognitive Performance (Z-score)</measure>
    <time_frame>3 months post operatively</time_frame>
    <description>Mean change on composite scores (z-score) for memory and executive function measures.
Memory measures: Hopkins Verbal Learning Test-Revised and the Brief Visuospatial Memory Test-Revised.
Executive function measures: the Trail Making Test (Army, 1944), Digit-symbol substitution and Symbol Search subtests of the Processing Speed Index of the Wechsler Adult Intelligence Scale-III (WAIS-III; Wechsler, 1997) and the Controlled Oral Word Association subtest of the Multilingual Aphasia Examination.
The outcomes were constructed as summed z-score composites. They are scaled as standard deviations. Thus, a score of 0 was central on each composite, and 95% of the scores would fall within -2.0 and +2.0. While there is no minimum or maximum value is rare for any score (&lt;1%) to fall outside the -3.0 to +3.0 range.
Higher scores (and thus positive change value) indicate an improvement of function.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Lumbar Spondylosis</condition>
  <condition>Cervical Spondylosis</condition>
  <condition>Hip Osteoarthritis</condition>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inhalational anesthesia with isoflurane</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>total intravenous anesthesia with propofol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>inhalation anesthesia with isoflurane vs. TIVA with propofol</intervention_name>
    <description>variable depending upon patient</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Diprivan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients (aged 65 years or older) scheduled for elective spine or major joint
             replacement (total hip or total knee arthroplasty) at Duke University Medical Center
             or the Durham VA Medical Center

        Exclusion Criteria:

          -  not fluent in English and able to comprehend the English language

          -  have severe visual or auditory handicaps

          -  Carry a diagnosis of dementia or score &lt; 18 on the Mini-Mental State Examination
             (MMSE) as calculated from the Modified Mini-Mental State (3MS) (see D4 below)

          -  have allergies to eggs, propofol, isoflurane, fentanyl, remifentanil, or pregabalin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Terri G Monk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VAMC</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2008</study_first_submitted>
  <study_first_submitted_qc>November 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2008</study_first_posted>
  <results_first_submitted>December 24, 2014</results_first_submitted>
  <results_first_submitted_qc>March 23, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 26, 2015</results_first_posted>
  <last_update_submitted>March 23, 2015</last_update_submitted>
  <last_update_submitted_qc>March 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>spinal, joint</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
    <mesh_term>Osteoarthritis, Hip</mesh_term>
    <mesh_term>Spondylosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Isoflurane</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>200 patients were consented. One person dropped out prior to baseline testing.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Isoflurane</title>
          <description>Inhalational anesthesia with isoflurane</description>
        </group>
        <group group_id="P2">
          <title>Propofol</title>
          <description>Total intravenous anesthesia with propofol</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Isoflurane</title>
          <description>Inhalational anesthesia with isoflurane</description>
        </group>
        <group group_id="B2">
          <title>Propofol</title>
          <description>Total intravenous anesthesia with propofol</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="98"/>
            <count group_id="B2" value="101"/>
            <count group_id="B3" value="199"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.38" lower_limit="66" upper_limit="86"/>
                    <measurement group_id="B2" value="73.13" lower_limit="65" upper_limit="91"/>
                    <measurement group_id="B3" value="73.25" lower_limit="65" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Neurocognitive Performance (Z-score)</title>
        <description>Mean change on composite scores (z-score) for memory and executive function measures.
Memory measures: Hopkins Verbal Learning Test–Revised and the Brief Visuospatial Memory Test–Revised.
Executive function measures: the Trail Making Test (Army, 1944), Digit-symbol substitution and Symbol Search subtests of the Processing Speed Index of the Wechsler Adult Intelligence Scale-III (WAIS-III; Wechsler, 1997) and the Controlled Oral Word Association subtest of the Multilingual Aphasia Examination.
The outcomes were constructed as summed z-score composites. They are scaled as standard deviations. Thus, a score of 0 was central on each composite, and 95% of the scores would fall within -2.0 and +2.0. While there is no minimum or maximum value is rare for any score (&lt;1%) to fall outside the -3.0 to +3.0 range.
Higher scores (and thus positive change value) indicate an improvement of function.</description>
        <time_frame>3 months post operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Isoflurane</title>
            <description>Inhalational anesthesia with isoflurane</description>
          </group>
          <group group_id="O2">
            <title>Propofol</title>
            <description>Total intravenous anesthesia with propofol</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Neurocognitive Performance (Z-score)</title>
          <description>Mean change on composite scores (z-score) for memory and executive function measures.
Memory measures: Hopkins Verbal Learning Test–Revised and the Brief Visuospatial Memory Test–Revised.
Executive function measures: the Trail Making Test (Army, 1944), Digit-symbol substitution and Symbol Search subtests of the Processing Speed Index of the Wechsler Adult Intelligence Scale-III (WAIS-III; Wechsler, 1997) and the Controlled Oral Word Association subtest of the Multilingual Aphasia Examination.
The outcomes were constructed as summed z-score composites. They are scaled as standard deviations. Thus, a score of 0 was central on each composite, and 95% of the scores would fall within -2.0 and +2.0. While there is no minimum or maximum value is rare for any score (&lt;1%) to fall outside the -3.0 to +3.0 range.
Higher scores (and thus positive change value) indicate an improvement of function.</description>
          <units>z score</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Memory measures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".09" lower_limit="-3.3" upper_limit="3.3"/>
                    <measurement group_id="O2" value="-.20" lower_limit="-3.3" upper_limit="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Executive Function measures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.42" lower_limit="-8.0" upper_limit="4.4"/>
                    <measurement group_id="O2" value=".01" lower_limit="-8.0" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Only unexpected adverse events that were related to the study were collected.</desc>
      <group_list>
        <group group_id="E1">
          <title>Isoflurane</title>
          <description>Inhalational anesthesia with isoflurane</description>
        </group>
        <group group_id="E2">
          <title>Propofol</title>
          <description>Total intravenous anesthesia with propofol</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Deborah Attix, PhD</name_or_title>
      <organization>Duke University Medical Center</organization>
      <phone>919-668-2846</phone>
      <email>deborah.koltai@dm.duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

